PRC1 and cancer: Thus, it is of great interest to develop small molecules and PROTACS that would either specifically target a discrete PRC1 complex or at least discriminate between cPRC1 and vPRC1 complexes, particularly in the context of cancers with high levels of H2AK119ub1, like BAP1 mutant tumors.